U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H15N3O2.ClH
Molecular Weight 269.727
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PARDOPRUNOX HYDROCHLORIDE

SMILES

Cl.CN1CCN(CC1)C2=C3OC(=O)NC3=CC=C2

InChI

InChIKey=NQRIKTDKFHAOKC-UHFFFAOYSA-N
InChI=1S/C12H15N3O2.ClH/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9;/h2-4H,5-8H2,1H3,(H,13,16);1H

HIDE SMILES / InChI

Molecular Formula C12H15N3O2
Molecular Weight 233.2664
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pardoprunox is a partial D2/3 dopamine receptor agonist and full 5-HT1A serotonin receptor agonist. Partial D(2/3) dopamine (DA) receptor agonists provide a novel approach to the treatment of the motor symptoms of Parkinson's disease that may avoid common dopaminergic side effects, including dyskinesia and psychosis. Pardoprunox passed phase III clinical trial for the treatment of Parkinson's disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.5 null [pKi]
8.1 null [pKi]
8.6 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PARDOPRUNOX

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
New frontiers in the pharmacological management of Parkinson's disease.
2008 Jul
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease.
2009
The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders.
2010 Aug
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
2010 Aug
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
2010 Dec
Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
2010 Oct 15
Patents

Sample Use Guides

Pardoprunox was titrated to each patient’s optimal dose (9–45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks.
Route of Administration: Oral
At cloned human dopamine D2 receptors, pardoprunox (SLV308) acted as a potent but partial agonist (pEC50 = 8.0) with an efficacy of 50% on forskolin-stimulated cAMP accumulation. At human recombinant dopamine D3 receptors, SLV308 acted as a partial agonist in the induction of [(35)S]GTPgammaS binding (an intrinsic activity of 67%; pEC50 = 9.2). SLV308 acted as a full 5-HT1A receptor agonist on forskolin-induced cAMP accumulation at cloned human 5-HT1A receptors but with low potency (pEC50 = 6.3).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:36:59 GMT 2023
Edited
by admin
on Fri Dec 15 16:36:59 GMT 2023
Record UNII
U40903X6V8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PARDOPRUNOX HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
DU-126891 HYDROCHLORIDE
Code English
PARDOPRUNOX HYDROCHLORIDE [USAN]
Common Name English
DU 126891 HYDROCHLORIDE
Code English
DU-126891 HCL
Code English
Pardoprunox hydrochloride [WHO-DD]
Common Name English
2(3H)-BENZOXAZOLONE, 7-(4-METHYL-1-PIPERAZINYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
PARDOPRUNOX HCL
Common Name English
7-(4-Methylpiperazin-1-yl)-1,3-benzoxazol-2(3H)-one monohydrochloride
Systematic Name English
SLV-308 HYDROCHLORIDE
Code English
SLV 308 HYDROCHLORIDE
Code English
Code System Code Type Description
NCI_THESAURUS
C81081
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
ChEMBL
CHEMBL2103832
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
DRUG BANK
DBSALT002129
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
FDA UNII
U40903X6V8
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
PUBCHEM
6918524
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
SMS_ID
300000044494
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
CAS
269718-83-4
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
USAN
UU-84
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
EPA CompTox
DTXSID80949746
Created by admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY